Mackenzie Hancock
Positions
Master's Student
Brain Neurorehabilitation Laboratory | BNR, Grad Students
Master's Student
Cumming School of Medicine, Department of Clinical Neurosciences
Contact information
Web presence
Preferred method of communication
mack.hancock@ucalgary.ca
Background
Biography
Mack, originally from Kingston, Ontario, completed his undergraduate degree in Neuroscience at Dalhousie University and is a Master's student in the Clinical Neuroscience program. His research is focused on the complexities of persisting post-concussion symptoms (PPCS). His current work involves two primary projects: a Phase 1 randomized double-blinded controlled trial examining the safety, feasibility, and efficacy of psilocybin-assisted therapy combined with Acceptance and Commitment Therapy (ACT) for adults with PPCS. Additionally, he is involved in a Phase 2 clinical trial conducted across the University of Calgary, Vancouver Island University, and the University of British Columbia, investigating the efficacy of psilocybin-assisted therapy alongside ACT for treating Post-Traumatic Stress Disorder (PTSD) in survivors of intimate partner violence (IPV), focusing on the reduction of PTSD symptoms and improvements in related areas such as depression, anxiety, cognitive flexibility, and quality of life. Outside of the lab, Mack enjoys golfing, skiing and being outdoors. In his free time, Mack enjoys golfing, skiing, and spending time with friends.
Projects
This Phase 1 clinical trial evaluates the safety, feasibility, and efficacy of psilocybin-assisted therapy in adults with persistent post-concussion symptoms (PPCS). Participants receive either a single high-dose or single low-dose of psilocybin, combined with five sessions of Acceptance and Commitment Therapy (ACT). The study aims to evaluate the safety and feasibility of this intervention, as well as its effectiveness in alleviating symptoms such as cognitive flexibility, anxiety, depression, PTSD, headaches, dizziness, sleep, and quality of life.
This Phase 2 clinical trial investigates the efficacy of psilocybin-assisted therapy for treating PTSD in survivors of intimate partner violence (IPV). Participants receive either a single high-dose or single low-dose of psilocybin, combined with five sessions of Acceptance and Commitment Therapy (ACT). The study focuses on improving PTSD symptoms in survivors of IPV, while also assessing outcomes such as depression, anxiety, cognitive flexibility, and quality of life. Conducted at the University of Calgary, Vancouver Island University, and the University of British Columbia, this research aims to explore psilocybin as a novel therapeutic intervention for trauma-related disorders.
Awards
- Canadian Institutes of Health Research (CIHR) Canada Graduate Scholarships Master's Award, Canadian Institutes of Health Research (CIHR). 2025
Are you the profile owner?
Login to edit.